Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
-
BUSINESS Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
-
BUSINESS Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
-
ACADEMIA Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
-
REGULATORY New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
-
BUSINESS Jevtana Supply Crunch amid Demand Spike Already Affecting Patients in Japan
May 7, 2024
-
BUSINESS Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
-
BUSINESS Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
-
BUSINESS Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
May 1, 2024
-
REGULATORY Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
-
BUSINESS Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
April 26, 2024
-
REGULATORY Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
April 25, 2024
-
BUSINESS Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
-
BUSINESS Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease
April 24, 2024
-
REGULATORY Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
-
REGULATORY MHLW Proposes Simplified Generic Delisting Scheme
April 22, 2024
-
REGULATORY More Unexpected Substances in Kobayashi’s Beni-Koji Supplements: MHLW
April 22, 2024
-
REGULATORY MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
-
ORGANIZATION Doctors’ Lobby Objects MOF Proposal for CEA Use in Reimbursement Decisions
April 18, 2024
-
REGULATORY MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…